Condition
Esophageal Cancer, Squamous Cell
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Enrolling By Invitation1
Recruiting1
Unknown1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT03301454Phase 2TerminatedPrimary
Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer
NCT07359417Phase 1Recruiting
MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma
NCT06984055Enrolling By InvitationPrimary
Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
NCT03126708Phase 2UnknownPrimary
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Showing all 4 trials